Zogenix Reports Second Quarter 2012 Financial Results
08 août 2012 16h01 HE
|
Zogenix
Reiterates 2012 Financial Guidance
Conference Call and Webcast Today, August 8th, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) Second Quarter 2012 Highlights...
Zogenix Repays Outstanding Loan With Oxford Finance LLC and Silicon Valley Bank
01 août 2012 08h30 HE
|
Zogenix
SAN DIEGO, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Conference Call and Webcast to Present Second Quarter 2012 Financial Results
31 juil. 2012 07h30 HE
|
Zogenix
SAN DIEGO, July 31, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix and Battelle Launch "Less is More" DosePro(R) Marketing Campaign
30 juil. 2012 07h30 HE
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, July 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Zogenix Prices Public Offering of Common Stock and Warrants to Purchase Common Stock
24 juil. 2012 09h04 HE
|
Zogenix
SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
23 juil. 2012 16h12 HE
|
Zogenix
SAN DIEGO, July 23, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of Zohydro ER(TM) New Drug Application (NDA) for Treatment of Chronic Pain
16 juil. 2012 07h30 HE
|
Zogenix
SAN DIEGO, July 16, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia
12 juil. 2012 07h30 HE
|
Zogenix
Patient Screening and Enrollment Underway With Results Anticipated Before Year-End
First-in-Class Needle-Free Once-Monthly Formulation Using DosePro® Delivery System
SAN DIEGO, July 12,...
Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL(R) DosePro(R)
07 juin 2012 07h30 HE
|
Zogenix
SAN DIEGO, June 7, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)
30 mai 2012 07h30 HE
|
Zogenix
SAN DIEGO, May 30, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...